Yesterday morning, legal marijuana investors woke up to this…
GW Pharmaceuticals (NASDAQ: GWPH), one of the five stocks I told you to own in 2016, soared at the open after the company announced positive phase III trial results.
GW Pharmaceuticals has developed a cannabis-related drug for children that suffer from severe epilepsy. And with this latest news, the company can now use its data to file for FDA approval. Once approved, this will be the first cannabis-derived medicine to ever be approved by the FDA.
If you took my advice back in December, congratulations on doubling your money. If you didn’t, don’t worry. Because there’s more of this to come.
Just Getting Started
If you’re a regular reader of these pages, you know I’m extremely bullish on the legal marijuana space. Quite frankly, it’s just the easiest money to be made in the market today.
Prohibition in the U.S. is on its way out.
In Canada, it’ll officially be over next year, thanks to the country’s new Prime Minister, Justin Trudeau. And in Mexico, the Supreme Court has given the nod to allow Mexican citizens to grow their own marijuana.
As I’ve mentioned in the past, we are at the dawn of a North American legal marijuana trade that’s already worth billions. And this thing is just getting started.
What Merrill Lynch Secretly Likes
While GWPH shareholders are doing backflips now that phase III trials have shown success, this is just one in a portfolio of legal marijuana stocks that are making investors rich.
From growers to retailers to testing companies, the opportunities are endless.
The biggest opportunities are likely to be found in what’s called “Life Science Tools.” This is basically equipment that’s used to test marijuana for potency and quality. Certainly analysts at Merrill Lynch are bullish.
Just a few months ago, a 45-page equity report from Merrill Lynch was leaked to a reporter in Philadelphia. This report noted that estimates for the equipment market could reach $100 million by 2020. Folks, that’s less than four years away.
Join Wealth Daily today for FREE. We’ll keep you on top of all the hottest investment ideas before they hit Wall Street. Become a member today, and get our latest free report: “The Top Three Biotech Stocks”
It contains full details on biotech stocks that are hidden in the haystack.
Of course, for investors, there are no pure play marijuana testing companies. At least none that are publicly traded. However, there is one private company that you can invest in if you’re an accredited investor. And quite frankly, this is one of the most lucrative marijuana testing companies in the United States, already generating millions in revenue.
In two weeks, I’ll be revealing the name of this company, along with all the specific details on how you can invest in this company without having to buy shares on the public markets. But to get access to this deal, you must be a member of my Green Chip Stocks private investment community.
Green Chip Stocks focuses on renewable energy, organic food, and legal marijuana markets. The latter is where we’re making most of our money these days. And not just on private deals.
In fact, three of our legal marijuana stocks are poised to deliver gains in excess of what GWPH delivered on Monday. Two are already up over 90%!
These are three Canadian marijuana plays that have already done deals with the Canadian government to take full advantage of legalization, which is set for approval at the end of the year.
To a new way of life and a new generation of wealth…
Jeff Siegel
Check us out on YouTube!
@JeffSiegel on Twitter
Jeff is the founder and managing editor of Green Chip Stocks. For more on Jeff, go to his editor’s page.
